In the western world, endometrial carcinoma (EC) is the most common cancer of the female genital tract. The annual incidence has been estimated at 10 --20 per 100 000 women. Two clinicopathological variants are recognized: the estrogen related (type I, endometrioid) and the non-estrogen related (type II, non-endometrioid).The clinicopathological differences are paralleled by specific genetic alterations, with type I showing microsatellite instability and mutations in phosphatase and tensin homologue deleted on chromosome 10, PIK3CA, K-RAS and CTNNB1 (b-catenin), and type II exhibiting TP53 mutations and chromosomal instability. Some non-endometrioid carcinomas probably arise from pre-existing endometrioid carcinomas as a result of tumor progression and, not surprisingly, some tumors exhibit combined or mixed features at the clinical, pathological and molecular levels. In EC, apoptosis resistance may have a role in tumor progression. Understanding pathogenesis at the molecular level is essential in identifying biomarkers for successful targeted therapies. In this review, the genetic changes of endometrial carcinogenesis are discussed in the light of the morphological features of the tumors and their precursors.
INTRODUCTION
In western countries, endometrial carcinoma (EC) is the most common cancer of the female genital tract. EC occurs in peri-and postmenopausal women, although it may also be present in premenopausal women, particularly in the setting of hyperestrogenism. From a clinical viewpoint, EC falls into two different types, so-called types I and II. 1 Type I tumors are low-grade and estrogen-related endometrioid endometrial carcinomas (EECs) that usually develop in perimenopausal women and coexist or are preceded by endometrial hyperplasia. In contrast, type II tumors are non-endometrioid endometrial carcinomas (NEECs). These aggressive tumors that occur in older women, are unrelated to estrogen stimulation and arise occasionally in endometrial polyps or from precancerous lesions in atrophic endometrium.
Over the last 15 years, knowledge about the molecular genetics of EC has increased notably. However, some issues remain to be elucidated and will be discussed in this review.
MOLECULAR FEATURES OF TYPES I AND II EC
It has been demonstrated that the molecular genetic alterations involved in the development of EEC (type I) differ from those of NEEC (type II). 2 --4 First, complementary DNA (cDNA) analysis clearly shows that EEC and NEEC have different gene expression profiles. Moreover, whereas EEC shows microsatellite instability (MI) and mutations in the phosphatase and tensin homologue deleted on chromosome 10 (PTEN), PIK3CA, K-RAS and b-catenin genes, NEEC have alterations of p53, loss of heterozygosity (LOH) on several chromosomes, as well as other molecular alterations (STK15, p16, E-cadherin and C-erbB2).
MI was initially noted in cancers of patients with the hereditary non-polyposis colorectal carcinoma (HNPCC), but also in sporadic colon cancers. EC is the second most common tumor found in HNPCC patients. MI is seen in 75% of EC associated with HNPCC, but also in 25 --30% of sporadic EC. 5 --8 HNPCC patients have an inherited germline mutation in MLH1, MSH2, MSH6 or PMS2. MI occurs more frequently in EEC (30%) than in NEEC. In sporadic tumors, MLH1 inactivation by promoter hypermethylation is the main cause of mismatch repair deficiency. 9 The MI-associated mismatch repair deficiency leads to the accumulation of mutations in coding and non-coding DNA sequences. Some small short-tandem repeats, like mononucleotide repeats, located within the coding sequence of some important genes; (BAX, IGFIIR, MSH3, MSH6, MBD4, CHK1, CASP5, ATR, ATM, BML, RAD50, BCL10 and APAF1) are targets in the process of tumor progression of MI þ EC. Mutations in these tracts are interpreted as secondary events in cancers with MI. 10, 11 The tumor-suppressor gene PTEN is frequently abnormal in EC. 12 --14 LOH at chromosome 10q23 occurs in 40% of EC. 15 Somatic PTEN mutations are also common in EC, and they are almost exclusively restricted to EEC, occurring in 37 --61% of them and lead to activation of the PI3K/AKT pathway. There are many evidences showing that EECs with mutations in PTEN have genomic instability. 16 For that reason, some authors have suggested to treat patients with PARP inhibitors. 17 Mutations in PIK3CA may contribute to the alteration of the phosphatidylinositol 3 kinase (PI3K)/AKT signaling pathway in EC. 18 --20 PI3K is a heterodimeric enzyme consisting of a catalytic subunit (p110) and a regulatory subunit (p85).The PIK3CA gene codes for the p110a catalytic subunit of PI3K. A high frequency of mutations in the PIK3CA gene has been reported recently in EC. Mutations are predominantly located in the helical (exon 9) and kinase (exon 20) domains, but they can occur also in exons 1 to 7. 21 PIK3CA mutations occur in 24 --39% of the cases, and coexisted frequently with PTEN mutations. PIK3CA mutations, particularly in exon 20, have been associated with adverse prognostic factors such as high-grade and myometrial invasion. Although initially described in EEC, PI3KCA mutations also occur in NEEC, and also mixed EEC --NEEC. 22, 23 Furthermore, gene expression profile differences in the PI3K --AKT signaling pathway identify two subgroups of highgrade EC with different molecular alterations (PI3K/AKT pathway versus p53 alterations), which may play distinct roles in endometrial carcinogenesis. 24 Moreover, mutations in PIK3RI (p85a), the inhibitory subunit of PI3K, have been detected in 43% of EEC, and 12% of NEEC. 25 Among AKT targets, downstream effector mammalian target of rapamycin (mTOR) is of particular interest. mTOR inhibitors have been recently developed as potential anticancer agents. Tumors associated with PTEN inactivation, like EC, are particularly susceptible to the therapeutic effects of mTOR inhibitors. Pharmacological inhibition of mTOR in PTEN þ /À mice has shown reduced neoplastic proliferation, tumor size and S6K activity. 26 Moreover, the use of dual PI3K --mTOR has been proposed as a targeted therapy, because they may target p110a, b and d isoforms, mTORC1 and mTORC2. 27 These inhibitors are expected to be effective in cancers (like EC) with PTEN mutations, PIK3CA mutations and receptor tyrosine kinase-dependent activation.
The Rat Sarcoma Viral Oncogene Homolog (Ras)--Raf protooncogene serine/threonine-protein kinase (Raf)--Extracellular Signal-Regulated Kinase kinase (MEK)--Extracellular SignalRegulated Kinase (ERK) signaling pathway plays an important role in EC. The frequency of K-RAS mutations in EC ranges between 10 and 30%. 28 BRAF, another member of the RAS --RAF --MEK --ERK pathways is very infrequently mutated in EC. 29 Recent studies have demonstrated that RASSF1A inactivation by promoter hypermethylation may contribute significantly to increased activity of the RAS --RAF --MEK --ERK signaling pathway. 30 There are several evidences suggesting that the fibroblast growth factor (FGF) signaling pathway is important in EC. Recent studies have shown that EC presents frequent inactivation of SPRY-2, a protein that is involved in the negative regulation of the FGFR pathway. 31 Moreover, somatic mutations in FGFR2, identical to the germline mutations associated with craniosynostosis and skeletal dysplasia syndromes, have been recently detected in 10 --12% of EC, particularly in EEC (16%).
32 --34 FGFR-2 is of special interest, since it is a possible target for therapeutic approaches.
Mutations in exon 3 of b-catenin gene (CTNNB1) occur in 14 to 44% of EC, 35 --37 and result in stabilization of the protein, cytoplasmic and nuclear accumulation, and participation in signal transduction and transcriptional activation through the formation of complexes with DNA binding proteins. They appear to be independent of the presence of MI, and the mutational status of PTEN and K-RAS. Mutations are homogeneously distributed in different areas of the tumors, which suggest that they do play a role in early steps of endometrial tumorigenesis. The presence of a cytoplasmic and nuclear b-catenin immunoreactivity in some ECs that did not show a mutation in CTNNB1 suggests that alterations in other genes of the Wnt/b-catenin/LEF-1 pathway may be responsible for the stabilization and putative transcription activator role of b-catenin in these tumors. 38, 39 In contrast to EEC, NEEC show P53 mutations (90%), inactivation of p16 (40%) and E-cadherin (80 --90%), c-erbB2 amplification (30%), alterations in genes involved in the regulation of the mitotic spindle checkpoint (STK15) and LOH at multiple loci, reflecting the presence of chromosomal instability. 40 --44 Although P53 mutations occur in 90% of NEEC, they are only present in 10 --20% of EEC, which are mostly grade 3 tumors. 45 Inactivation of the cell cycle regulator p16 is also more frequent in NEEC (40%) than in EEC (10%). The underlying mechanism is not clear, but probably involves deletion and promoter hypermethylation. Reduced expression of E-cadherin is frequent in EC, and may be caused by LOH or promoter hypermethylation. In fact, LOH at 16q22.1 is seen in almost 60% of NEEC, but only in 22% of EEC. CerbB2 overexpression and amplification are also seen more frequently in NEEC (43 and 29%) than in EEC. However, the most typical molecular feature of NEEC is chromosomal instability. This phenomenon is characterized by the presence of widespread chromosomal gains and losses, which reflect the presence of aneuploidy. cDNA arrays have demonstrated that NEEC usually show upregulation of genes (STK15, BUB1 and CCNB2) that are involved in the regulation of the mitotic spindle checkpoint. One of them, STK15, which is essential for chromosome segregation and centrosome functions, is frequently amplified in NEEC.
Among NEEC, clear cell carcinomas show specific features. Based on the similarities between ovarian and endometrial clear cell carcinoma, it has been suggested that both types of tumors may exhibit similar alterations, including mutations in PIK3CA and PTEN. Mutation of the ARID1A gene and loss of the corresponding protein BAF250a has recently been described as a frequent event in clear cell and endometrioid carcinomas of the ovary. In a recent study, these changes have been found in 29% of grade 1 or 2 and 39% of grade 3 EEC, 18% of uterine serous carcinomas and 26% of uterine clear cell carcinomas. In a different study, uterine lowgrade EEC have also shown a relatively high-frequency loss of ARID1A expression (26%) and ARID1A mutations (40%). 46, 47 cDNA array studies have demonstrated that the expression profiling of EEC is different from that of NEEC. Some of the data obtained from these studies have helped in a better diagnosis and prognosis. In one study, 48 191 genes exhibited a greater twofold differences between 19 EECs and 16 NEECs. One of the genes, trefoil factor 3 (TFF3) was significantly upregulated in EECs, while increased expression of folate-binding protein (FOLR) was seen in NEECs. Subsequent studies demonstrated that TFF3 was highly expressed at gene and protein level in high-grade EECs, suggesting that TFF3 could be a novel serum marker for early detection and/or monitoring EEC patients. 49 Moreover, overexpression of FOLR and mesothelin was found to be associated with NEEC, 50 and also with shortened progression-free survival in EC. 51 In a different study, a different expression profile was seen between EEC and NEEC, and the differences involved 66 genes. Interestingly, estrogen-regulated genes were upregulated in EEC, whereas NEEC showed increased expression of genes involved in the regulation of the mitotic spindle checkpoint. 52 A third study demonstrated differentially expression of 1055 genes between EECs and serous carcinomas. Genes that were differentially expressed were IGF2, PTGS1, p16, TFF3, FOXA2 and MSX2.
53
A different study identified 315 genes that statistically differentiated EEC from NEEC. 54 Among the genes listed for EEC are ras-related protein RAB14, a2-catenin, human transforming growth factor b3 and ILGF1. In contrast, aldolase C was one of the major discriminators for NEEC. In a different study, it was seen that the tumors (ovarian and uterine) with b-catenin alterations, showed common gene expression profile. 55 Recently, a low-density cDNA microarray approach identified five differentially expressed genes in EEC and NEEC, NDC80, BUB1, FUT8, ANXA4 and BBC3. 56 Moreover, a different expression profile was also found between EC associated with MI and stable EC. Interestingly, two members of the secreted frizzled related protein family (SFRP1 and SFRP4) were more frequently downregulated in EC with MI. 57 Molecular profiling has also been evaluated in relationship with other prognostic parameters. A recent study with an array containing 492 genes was used to generate gene expression profiles in correlation with histologic type and grade, and stage. 58 
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One cluster contained 38 genes that were upregulated in samples of the cluster representing the most advanced disease; and one of these genes was CCNE2. Gene expression profiling also has revealed that some genes (Apolipoprotein E) are differentially expressed in poorly differentiated tumors. 59 Our group has also identified, by c-DNA array studies, upregulation of RUNX1/AML1 and ERM/ETV5 in EC, 60 and suggested an implication of such genes in myometrial invasion. One study compared the expression profiles of similar histological subtypes of ovarian and ECs; and showed that clear cell carcinomas had a very similar profile, regardless of the organ of origin. In contrast, differences were seen when comparing endometrioid and serous carcinomas of ovarian and endometrial origin.
We have recently performed a cDNA microarray analysis to identify new genes and pathways involved in endometrial carcinogenesis. We used cDNA microarrays containing 6386 different genes to analyze gene expression profiles in 24 EECs and 8 normal endometria (NE) samples. After supervised analysis of the microarray data, there was an at least twofold difference in expression between EEC and NE in 159 genes (adjusted P-values o0.07, unadjusted P-values o0.001), including, among others, tumor-suppressor genes (SMAD4 and WT1), genes involved in endometrial homeostasis (IGF1, IGF2), immune modulation (CD74, LCN2, IL2, IL5R and IL7R), the Wnt pathway (WNT5A and DVL2), mismatch repair (PMS1), cell signaling (FGFR1, PGFRA, PLXNB1, KSR, LYN, FYN, PRKCD, STAT3 and STAT12), components of the extracellular matrix (SPARC, COL5A1, COL5A2, COL5A1, COL6A3 and COL15A1) and genes involved in extracellular matrix remodeling (MMP9 and MMP19). To validate the quality of our array data, a subset of genes (IGF1, IGF2, WNT5A, WT1, PMS1, PRKCD and FGFR1) differentially expressed in normal endometrium and EECs were examined in all samples using semi-quantitative reverse transcriptase --PCR and also in an independent series of EECs obtaining similar results, with the only exception was PRKCD, which just failed to reach significance, with a P-value of 0.079 (Table 1 ; Figure 1 ). In addition, CD74 and Smad4, were immunohistochemically analyzed in a tissue microarray containing 190 ECs, including both EEC and NEEC, in order to further validate microarray data and to gain insights into the role of these proteins in EC (Table 2 ). Immunohistochemical analysis demonstrated that CD74, which was not expressed in normal endometrium, was expressed in 123 (80.4%) tumors and was associated with the endometrioid phenotype and lower grade. Finally, Smad4 expression was reduced in 75 (57.3%) tumors, including 17 (13%) cases with complete absence of Smad4 expression in neoplastic epithelial cells ( Figure 2 ).
ECs not fitting within the dualistic (type I versus type II) model The classification of EC into two groups (type I and type II) is artificial and too rigid and the dualistic model needs to be challenged ( Figure 3) . In daily practice, pathologists are faced with tumors showing combined or hybrid morphologic and molecular characteristics (often endometrioid and serous tumors). Furthermore, even if serous and clear cell carcinomas have been classified within the same category of tumors as they are more aggressive than EC, recent studies have shown that these are in fact distinct tumor types, as they exhibit different clinical, immunohistochemical and molecular features. When an EC has an admixture of EEC and EC, with the minor component representing at least 10% of the neoplasm, the tumor should be classified as a mixed carcinoma. Based on molecular analysis, it has been suggested that the NEEC component originates as a result of tumor progression from a pre-existing EEC, because frequently these tumors retain the molecular alterations of typical EEC. There are some tumors that exhibit overlapping and intermediate features between EEC and NEEC and fail to show two distinct components. The term 'EC with ambiguous features' has been proposed for these carcinomas. 61 Their clinical and molecular features should be defined better. Moreover, the overlap between EEC and NEEC is also seen when we look for differences in the frequency of the main molecular alteration. The typical molecular alterations of EEC are occasionally seen in NEEC, while the typical molecular features of NEEC are also detected in EEC. Occasionally, undifferentiated carcinomas are associated with well-or moderately differentiated EEC. The term dedifferentiated carcinoma has been used to designate such special type of tumor. Several groups of investigators have reported that the EECs with a tendency to develop a high-grade, undifferentiated carcinoma present MI as a frequent molecular genetic alteration. 62 However, MI is not seen in all cases and other, have P53 mutations.
Malignant mixed müllerian tumors (MMMT), (carcinosarconas or sarcomatoid carcinomas), are uncommon uterine neoplasms. They are composed by a bifasic pattern, with epithelial malignant elements and a sarcomatoid component. It has recently suggested from the molecular point of view that MMMT should be regarded as metaplastic carcinomas. 63 --65 Like sarcomatoid carcinomas of other locations, carcinosarcomas probably develop through epithelial-to-mesenchymal transition (EMT) in EC. Although the transient occurrence of the EMT phenomenon is important for myometrial invasion in conventional EC, MMMT show permanent expression of EMT leading to repression of epithelial markers (E-cadherin) and increased expression of mesenchymal markers including proteins involved in skeletal muscle development. All of these molecular changes are responsible for the appearance of the sarcomatous areas as well as the presence of heterologous differentiation. It has been recently seen that MMMT show HMGA2 overexpression, and a microRNA signature typical of EMT. 66, 67 MYOMETRIAL INVASION Deep myometrial invasion is an important prognostic factor. It correlates with high-grade components, vascular invasion and lymph node metastasis. EMT has recently been recognized as an important mechanism in invasion and metastasis. Different transcriptional repressors of E-cadherin have been identified, including the zinc-finger factors Snail and Slug, the two handed factors SIP-1 (Zeb-2) and EF1 (Zeb-1), and the bHLH factors E12/ E47 and Twist. Snail expression is increased and correlates inversely with E-cadherin inmunoreactivity in metastatic EC but not in the corresponding primary tumors. 68 Nevertheless, a significant negative correlation between E-cadherin decrease and Snail expression has also been found in primary EC. Furthermore, high Twist expression has been shown in invasive EC. Our group 69 has recently compared samples from the surface area and the myoinvasive front of EC in order to investigate whether the EMT program is activated in early stages of EC. We found increases in SLUG, ZEB1 and HMGA2 mRNA expression in the myoinvasive front of tumor samples, indicating the role of these transcriptional factors in endometrial tumor progression and invasion. Increase in Snail and Twist expression occurred concomitantly with decrease in E-cadherin expression at the myoinvasive front of early stage EC. For better understanding of the potential role of EMT in the genesis and development of ECC, an in vitro scenario mimicking this process was developed using IK V600E transformed EC cells. The overexpression of the BRAF missense mutation V600E leads to a persistent activation of ERK1/2 and increase in Snail protein levels as demonstrated by immunofluorescence and western blot analysis. expression has been seen as a result of b-catenin nuclear accumulation, in EC with CTNNB1 mutations. Transcription factor RUNX1/AML1 has been found to be upregulated in EC during invasion; and a cooperative role of ERM/ETV5 and RUNX1/AML1 during early steps of myometrial invasion has been proposed. 72 EECs with myometrial invasion show higher number of CD163-tumor macrophages and greater microvessel density than EECs without myometrial invasion. 73 In carcinomas confined to the corpus uteri (stage I), expression of hypoxia-inducible factor 1a subunit (HIF-1A) is associated with deep myoinvasion (stage IC). 73 Also, high-grade EECs have more macrophage infiltrates and microvessels than low-grade tumors. These findings suggest that enhanced tumor angiogenesis, triggered by stromal macrophages regulates the progression of EEC.
A proteomic approach has been recently taken to characterize specific components of the invasive front or reactive stroma by comparing the invasive area of a tumor with pure tumor and normal tissue from the same patients. 74 Some of these proteins have been already described as specific of the invasive tumor front, like Fascin1 in colorectal cancer, with a transient upregulation that promotes the acquisition of migratory and invasive phenotypes that lead to metastasis. Of interest resulted the identification of different enzymes involved in oxidative stress, as SOD1 or BLVRB. Reactive oxygen species (ROS) have been recently proposed to be involved in tumor metastasis. ROS is generated and ROS targets downstream molecules to trigger tumor metastasis, especially in the initial stage that includes EMT and cell migration.
APOPTOSIS RESISTANCE IN EC
Deregulation of apoptosis plays an important role in development and progression of cancer. The lack of response to such stimuli can originate a survival advantage, and the expansion of a population of neoplastic cells. Moreover, cells resistant to apoptosis are likely to escape the immune surveillance, but they may be also resistant to therapy.
Several of the molecular abnormalities that have been detected in EC may be associated with apoptosis deregulation. EEC show a high frequency of mutations in PTEN, which lead to constitutively active Akt, which in turn suppresses apoptosis triggered by various stimuli. Moreover, the recent evidence that nuclear factor (NF)-kB activation is frequent in EC 75 may explain the presence of apoptosis resistance by activation of target genes such as FLIP and Bcl-XL. P53 alterations, which are characteristic of NEEC, may also occur in EEC and they may have an impact in apoptosis at several different levels. Also, members of the Bcl-2 family of genes are abnormal in EC. In EC, divergent observations have been reported with respect to Bcl-2 and Bcl-xL. Some authors have found upregulated Bcl-xL and Bcl-2 in EC compared with normal tissue and have also been reported to be involved in development of metastases. However, others described high Bcl-2 levels in initial hyperplasia but decreased expression of Bcl-2 in EC thereby indicating a restrictive role for Bcl-2 in initial steps of EC development. Many pathways can control Bcl-2 expression and typical EC molecular alterations such as those involved in exacerbated PI3K/AKT signaling could trigger Bcl-2 family members overexpression. Resistance to extrinsic apoptotic pathway represents an excellent acquired phenotype for progression of different types of tumor malignances. One of the most important regulators of death receptor signaling is FLIP. 76 A direct evidence of the role of FLIP in TRAIL apoptosis resistance on EC cells is provided by treatment with specific small interfering RNA targeting FLIP. Transfection of EC cell lines with FLIP small interfering RNA produces a marked decrease in cell viability after TRAIL exposition. This is accompanied by activation of both caspase-8 and caspase-3 suggesting activation of the extrinsic pathway. Moreover, in EEC FLIP can be transcriptionally regulated by casein kinase-2 (CK2), a Ser/Thr kinase implicated in development and progression of many neoplasias. This data further points to CK2 as an important modulator of TRAIL sensitivity. 67, 68 In fact, CK2 b regulatory subunit has been found overexpressed in EC compared with normal tissue and to regulate cell proliferation and anchorage-independent cell growth. Recent studies have shown that FLIP may be regulated by a cellular complex composed by CK2 --BRAF --KSR1. 77--80 This is interesting because that will connect apoptosis resistance with the RAS--RAF--MEK--ERK signaling pathway. The kinase suppressor of RAS 1 (KSR1) is considered a scaffold protein that interacts and regulates the intensity and duration of mitogen-activated protein kinase pathway. KSR1 can interact with different kinases of the RAS --RAF --MEK --ERK signaling pathway to enhance its activation. KSR1 is critical for Ras-induced transformation by active forms of Ras both in vitro and in vivo. KSR1 regulation of RAS --RAF --MEK --ERK has also been involved in modulation of apoptotic response to death receptors. It has been recently demonstrated that the expression of KSR1 is increased in EC suggesting a possible role in endometrial carcinogenesis. Inhibition of KSR1 expression by lentiviral delivered short hairpin RNA in ECCs resulted in a marked reduction of both proliferation and anchorage-independent cell growth properties of ECCs. Interestingly, inhibition of KSR1 expression sensitized resistant ECC lines to both TRAIL-and Fas-induced apoptosis by a mechanism dependent on downregulation of FLIP. 
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Apoptosis may be also subjected to targeted therapy. Proteasome inhibitors are currently used as chemotherapeutic drugs because of their ability to trigger cell growth arrest or apoptosis on several tumors. In many different types of tumor cells, Bortezomib and other proteasome inhibitors cause cell death by blocking NF-kB activity. However, in EC, proteasome inhibitors induce cell death, but, instead of blocking NF-kB, they increase its transcriptional activity. Proteasome-inhibitor induced cell death was accompanied by activation of caspases and apoptotic nuclear morphology. 81 Sorafenib was originally described as an inhibitor of b-and c-RAF kinase, but has also activity against several receptor tyrosine kinases, including vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor, FLT3, Ret and c-Kit. There is recent evidence showing that Sorafenib sensitize EC cells to TRAIL-induced apoptosis, by downregulating FLIP, and Mcl-1. 77 
RESISTANCE TO HYPOXIA AND TO IONIZING RADIATION TREATMENT
EC are treated by means of surgery with additional radiation. Although a high percentage of patients with EC present a favorable outcome, treatment fails in those with either advanced stage or high histological grade EC. Post radiotherapy recurrences are usually of poor prognosis, as they are usually associated with increased risk of metastases. They are treated by chemotherapy. Understanding the molecular and genetic mechanisms underlying either radio and or chemotherapy treatment resistance is of crucial importance for the establishment of new therapeutic targets, in order to improve the outcome of EEC.
Among the mechanisms in radioresistance, tumor hypoxia has been demonstrated to render tumors more resistant to ionizing radiation treatment. By reacting with the radiation-created broken ends of DNA, the oxygen fixes the damage and thus enhances radiation induced cell death. This phenomenon is known as the oxygen enhancement effect, which could render oxygenated cells three times more radiosensitive than hypoxic cells. Under hypoxic conditions, the oxygen enhancement effect is lost, and cells become more radioresistant (Figure 4) . Although the absence of oxygen is the major factor inducing radioresistance under hypoxic conditions, there are increasing evidences showing that signaling pathways activated under hypoxia may modulate cancer cells radioresistance.
Some investigators have addressed the molecular mechanisms involved in resistance to radiotherapy in EC. PR expression and polymorphisms in the gene coding for PR seem to play an important role. 82 Defective mismatch repair has also been looked at in this setting. In one study, 83 MLH1 promoter methylation and decreased MLH1/MSH2 expression were not predictive of recurrence in stage I EC, but 'de novo' MLH1 promoter methylation was occasionally detected during tumor progression in patients receiving radiation therapy. In another study, 84 alterations in the P53-suppressor gene were assessed in a series of patients with ECs with and without recurrences. Finally, three components of the Wnt pathway (APC, b-catenin and E-cadherin) were evaluated in a small series of patients with stage I EC in correlation with development of recurrence. 85 Important information has been obtained regarding the mechanisms of resistance to radiation, by comparing by immunohistochemistry tissue microarrays from post-radiation recurrences of EC with a group of primary EC. 86 Results have revealed that post-radiation recurrences exhibited increased expression b-catenin. In recent work, it has been showed that hypoxia-induced b-catenin nuclear translocation in EC Ishikawa and HEC-1A cell lines. Moreover, hypoxia induced an increase in TCF-4 reporter (Wnt reporter) activity in both EC cell lines previously cited. HIF-1a is another candidate that could be involved in conferring radioresistance to EC cells. HIF-1 is the most important mediator of hypoxia, as it controls the expression of 4100 genes. It has been recently shown that HIF-1a expression is increased in postradiation recurrences compared with primary EC, and that HIF-1a controlled classical NF-kB activation pathway and survival under hypoxia through RelA (p65) nuclear accumulation. 87 Moreover, in addition to the reported classical NF-kB activation pathway under hypoxia, we have found that the alternative NF-kB pathway is also activated under hypoxic conditions through HIF-1a-independent pathway. Although IKKa and IKKb kinases control RelA(p65) and p100 accumulation, p52 processing under hypoxia is exclusively IKKa dependent. Both classical and alternative NF-kB pathways enhanced EC cell survival under low oxygen tension. These results may have a clinical application, as targeting the signaling pathways on which hypoxic cell survival depends, may enable oncologists to overcome tumor progression and resistance to therapy. Figure 4 . Hypoxia induces resistance to radiotherapeutic treatment: Ishikawa (EC cell line) cells were seeded onto six-well plates. Cells were either exposed to hypoxic conditions (1% O 2 ) or maintained under normoxia (21% O 2 ) for 6 h, and then irradiated at the indicated doses. Cells were then cultured for additional 14 days to allow colony formation. After staining with MTT, the colony numbers were counted. The graphic shows how the presence of oxygen enhances sensitivity to ionizing radiation therapy.
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